Skip to main content
SpringerLink
Log in

Reduction of Serum LDL-C Levels

A Relationship to Clinical Benefits

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

The association between elevated serum cholesterol levels and cardiovascular risk was established several decades ago by studies such as the Framingham study and the Multiple Risk Factor Intervention Trial (MRFIT). Both primary and secondary prevention trials of cholesterol lowering, using HMG-CoA reductase inhibitors, have demonstrated clear benefits for lipid lowering in preventing both cardiovascular morbidity and mortality over a wide spectrum of coronary heart disease (CHD) risk. Even so, risk of events has been reduced by about 30% in these trials, leaving 70% of events occurring even in the presence of substantial cholesterol lowering. It is unknown whether further reduction of serum cholesterol levels will lower risk factors. The relationship between cholesterol lowering and cardiovascular risk, moreover, is not completely defined; it is unclear, at lower cholesterol levels, whether that relationship follows a threshold, a linear, or a curvilinear model. Early studies of low-density lipoprotein-cholesterol (LDL-C) lowering with HMG-CoA reductase inhibitors suggested that non-cardiovascular mortality might be increased at low serum LDL-C levels, however, these concerns have not been supported by subsequent clinical trials. Recent studies have shed further light on the potential benefits of lowering serum cholesterol levels beyond current guideline targets with HMG-CoA reductase inhibitors. More potent agents in development are likely to make such levels more readily achievable, as well as making guideline targets attainable for many of the large number of patients who currently fail to reach them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Fig. 1
Table II
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Bureau of Disease Study. Lancet 1997; 349: 1269–76

    Article  PubMed  CAS  Google Scholar 

  2. Steinberg D, Gotto Jr AM. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA 1999; 282: 2043–50

    Article  PubMed  CAS  Google Scholar 

  3. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and risk of coronary heart disease: Framingham Study. Ann Intern Med 1971; 74: 1–12

    PubMed  CAS  Google Scholar 

  4. Abbott RD, Wilson PW, Kannel WB, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: The Framingham Study. Arteriosclerosis 1988; 8: 207–11

    Article  PubMed  CAS  Google Scholar 

  5. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–8

    Article  PubMed  CAS  Google Scholar 

  6. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97

    Article  Google Scholar 

  7. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434–503

    Article  Google Scholar 

  8. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. JAMA 1999; 282: 2051–7

    Article  PubMed  CAS  Google Scholar 

  9. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events): principal results. Heart 1996; 75: 334–42

    Article  PubMed  CAS  Google Scholar 

  10. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. Eur Heart J 1997; 18: 1569–82

    Article  Google Scholar 

  11. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554–72

    Article  Google Scholar 

  12. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (LTAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–67

    Article  PubMed  CAS  Google Scholar 

  13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

    Article  Google Scholar 

  14. Kastelein JJP. The future of best practice. Atherosclerosis 1999; 143 Suppl. 1: S17–21

    Article  PubMed  CAS  Google Scholar 

  15. Wakugami K, Iseki K, Kimura Y, et al. Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J 1998; 62: 7–14

    Article  PubMed  CAS  Google Scholar 

  16. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. BMJ 1991; 303: 276–82

    Article  PubMed  CAS  Google Scholar 

  17. Szatrowski TP, Peterson Jr AV, Shimizu Y, et al. Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort. J Chronic Dis 1984; 37: 569–84

    Article  PubMed  CAS  Google Scholar 

  18. Glueck CJ, Kelley W, Gupta A, et al. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1479 men in the National Health and Nutrition Examination Survey I. Metabolism 1997; 46: 625–33

    Article  PubMed  CAS  Google Scholar 

  19. Welty FK, Mittleman MA, Wilson PWF, et al. Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. Circulation 1997; 95: 825–30

    Article  PubMed  CAS  Google Scholar 

  20. Welty FK, Lahoz C, Tucker KL, et al. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham offspring population. Arterioscler Thromb Vasc Biol 1998; 18: 1745–51

    Article  PubMed  CAS  Google Scholar 

  21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7

    Article  PubMed  CAS  Google Scholar 

  22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22

    Article  PubMed  CAS  Google Scholar 

  23. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  24. Sacks FM, Pfeffer MA, Moye LA, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9

    Article  PubMed  CAS  Google Scholar 

  25. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57

    Article  Google Scholar 

  26. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a metaanalysis of randomized controlled trials. JAMA 1999; 282: 2340–6

    Article  PubMed  CAS  Google Scholar 

  27. Jacobson TA. “The lower the better” in hypercholesterolemia therapy: a reliable clinical guideline? Ann Intern Med 2000; 133: 549–54

    PubMed  CAS  Google Scholar 

  28. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446–52

    Article  PubMed  CAS  Google Scholar 

  29. Pedersen TR. Aggressive lipid-lowering therapy: a clinical imperative. Eur Heart J 1998; 19 Suppl. M: M15–21

    PubMed  CAS  Google Scholar 

  30. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97: 1436–9

    Article  PubMed  CAS  Google Scholar 

  31. Pederson TR, Olsson AG. 4S results support AHA guidelines to reduce LDL-cholesterol to less than 100 mg/dl in patient with CHD [abstract]. Circulation 1997; 96 Suppl. I: 717

    Google Scholar 

  32. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440–5

    Article  Google Scholar 

  33. Gotto Jr AM. Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study population. Am J Cardiol 2000; 85: 8E–14E

    Article  PubMed  Google Scholar 

  34. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481–7

    Article  PubMed  CAS  Google Scholar 

  35. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–31

    Article  PubMed  Google Scholar 

  36. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–5

    Article  PubMed  CAS  Google Scholar 

  37. Ridker PM, Rifai N, Pitman, et al. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191–3

    Article  PubMed  CAS  Google Scholar 

  38. La Rosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001; 88: 291–3

    Article  Google Scholar 

  39. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643–50

    Article  PubMed  CAS  Google Scholar 

  40. Alfon J, Royo T, Garcia-Moll X, et al. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Throm Vasc Biol 1999; 19: 1812–7

    Article  CAS  Google Scholar 

  41. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153–62

    Article  Google Scholar 

  42. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 2000; 102: 157–65

    Article  PubMed  CAS  Google Scholar 

  43. Pitt B, Waters D, Brown WV, et al. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease: atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70–6

    Article  PubMed  CAS  Google Scholar 

  44. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285: 1711–8

    Article  PubMed  CAS  Google Scholar 

  45. LaRosa JC. Future clinical trials of lipid-lowering drugs. In: Gaw A, Shepherd J, editors. Lipids and Atherosclerosis Annual. Martin Dunitz Ltd, London, Lipids and atheroslcerosis annual, London 2001: 223-38

  46. Chung Y-S, Lee M-D, Lee S-K, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85: 1137–42

    Article  PubMed  CAS  Google Scholar 

  47. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355: 2218–9

    Article  PubMed  CAS  Google Scholar 

  48. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 200; 355: 2185-8

  49. Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162: 537–40

    Article  PubMed  CAS  Google Scholar 

  50. Kivipelto M, Helkala E-L, Hänninen T, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–51

    Article  PubMed  CAS  Google Scholar 

  51. Jick H, Zoenberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627–31

    Article  PubMed  CAS  Google Scholar 

  52. Rockwood K, Kirkland S, Hogan CB. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223–7

    Article  PubMed  Google Scholar 

  53. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309–14

    Article  PubMed  CAS  Google Scholar 

  54. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490–500

    Article  PubMed  CAS  Google Scholar 

  55. Vartiainen E, Puska P, Pekkanen J, et al. Serum cholesterol concentration and mortality from accidents, suicide and other violent causes. BMJ 1994; 309: 445–7

    Article  PubMed  CAS  Google Scholar 

  56. Iribarren C, Reed DM, Chen R, et al. Low serum cholesterol and mortality: which is the cause and which is the effect? Circulation 1995; 92: 2396–403

    Article  PubMed  CAS  Google Scholar 

  57. Wannamethee G, Shaper AG, Whincup PH, et al. Low serum total cholesterol concentrations and mortality in middle aged British men. BMJ 1995; 311: 409–13

    Article  PubMed  CAS  Google Scholar 

  58. Cullen P, Schulte H, Assmann G. The Munster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 1997; 96: 2128–436

    Article  PubMed  CAS  Google Scholar 

  59. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2274–82

    Article  PubMed  CAS  Google Scholar 

  60. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946–52

    Article  PubMed  CAS  Google Scholar 

  61. Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001; 322: 11–5

    Article  PubMed  CAS  Google Scholar 

  62. Bakker-Arkema RG, Nawrocki JW, Black DM. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 2000; 149: 123–9

    Article  PubMed  CAS  Google Scholar 

  63. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205–7

    Article  PubMed  Google Scholar 

  64. Holme I. Lipid lowering in the patient at risk: the next decade of discovery. Br J Cardiol 2000; 7: 223–30

    Google Scholar 

  65. Pedersen TR, Faergeman O, Holme I, et al. Effect of greater LDL-C reductions on prognosis: the Incremental Decrease in Endpoints through Aggressive Lipid lowering (IDEAL) Trial [abstract]. Atherosclerosis 1999; 144 Suppl. 1: 38

    Article  Google Scholar 

  66. LaRosa JC, for the TNT Steering Committee. Effect of lowering LDL-C beyond currently recommended minimum targets: the Treating to New Targets (TNT) study. Poster presented at the 13th International Symposium on Drugs Affecting Lipid Metabolism; 1998 May 30–June 3; Florence, Italy

  67. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504–8

    Article  PubMed  CAS  Google Scholar 

  68. Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethyl-glutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am J Cardiol 2000; 85: 178–83

    Article  PubMed  CAS  Google Scholar 

  69. Brown WV, Zedler BK, Bays HE, et al. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin [abstract]. Eur Heart J 2001; Suppl. 22: 270

    Google Scholar 

  70. Olsson A, Southworth H, Wilpshaar JW. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus atorvastatin [abstract]. Eur Heart J 2001; Suppl. 22: 253

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The author is Chairman of the TNT steering committee for Pfizer.

Author information

Authors and Affiliations

  1. SUNY Downstate Medical Center, University of New York Health Center at Brooklyn, 450 Clarkson Ave, Brooklyn, NY, 11203, USA

    John C. LaRosa

Authors
  1. John C. LaRosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John C. LaRosa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

LaRosa, J.C. Reduction of Serum LDL-C Levels. Am J Cardiovasc Drugs 3, 271–281 (2003). https://doi.org/10.2165/00129784-200303040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200303040-00006

Keywords

Search

Navigation